Intrexon, a developer of synthetic biology, has closed a $150 million Series F round of financing. New investors accounted for the majority of the round, with current investors, including affiliates of Intrexon’s chairman and CEO Randal J. Kirk and Third Security, taking the balance of the round. The Blacksburg, VA-based company is deploying its capabilities to design and produce novel and enhanced biological products across multiple industry sectors, including human therapeutics, protein production, industrial products, agricultural biotechnology and animal science. The funding will be used for additional channel collaborations, expansion of sales and marketing, and research and development.
